Qiang Sa

Prognostic significance of ctDNA mutations in advanced HER2-positive breast cancer treated with targeted therapy: A meta-analysis

Jialin Lin, Hangcheng Xu, Yiran Zhou, Qiang Sa et autres

BACKGROUND: Circulating tumor DNA (ctDNA) is a promising noninvasive biomarker in advanced breast cancer. In patients with advanced HER2-positive disease, responses to targeted therapy vary. The prognostic significance of ctDNA mutations across different genes and treatment regimens remains to be fully clarified. …

cn (code pays fourni par la source)

Abstract 7633: Dynamic monitoring and identification of reliable biomarkers to predict efficacy of bireociclib and fulvestrant: An exploratory ctDNA analysis of the BRIGHT-2 study

Yan Wang, Hangcheng Xu, Yiran Zhou, Liang Cui et autres

Abstract Background Although the novel cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor bireociclib demonstrated potent efficacy for hormone receptor -positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in the BRIGHT-2 study (NCT05077449), patient exhibited substantial heterogeneity in therapeutic efficacy—some …

cn (code pays fourni par la source)

Treatment for metastatic triple-negative breast cancer with homologous recombination deficiency: a Bayesian network meta-analysis

Hangcheng Xu, Yan Qiu Wang, Qiang Sa, Yiran Zhou et autres

BACKGROUND: Homologous recombination deficiency (HRD) is a key molecular feature in a subset of triple-negative breast cancer (TNBC). The optimal treatment strategy for metastatic TNBC with HRD remains unclear despite multiple therapeutic options. METHODS: A systematic search was performed in PubMed, Embase, …

cn, us (code pays fourni par la source)

Dynamic Monitoring and Identification of Reliable Biomarkers to Predict Efficacy of Bireociclib and Fulvestrant: An Exploratory ctDNA Analysis of the BRIGHT-2 Study

Binghe Xu, Yan Wang, Hangcheng Xu, Yiran Zhou et autres

cn, us, Éthiopie, fr (code pays fourni par la source)

Prognostic value of Ki-67 index in malignant phyllodes tumor of the breast: a multi-center real-world study

Yiran Zhou, Changyuan Guo, Yan Wang, Hangcheng Xu et autres

BACKGROUND: Malignant phyllodes tumor of the breast (MPTB) is a rare interstitial neoplasm, accounting for less than 1% of all types of breast tumors. It has the tendency for local recurrence and distant metastasis compared to benign PTB. A number of patients …

cn, us (code pays fourni par la source)

Associations between dynamic hematological indicators and outcomes in HR-positive, HER2-negative metastatic breast cancer treated with bireociclib or placebo plus fulvestrant: Findings from the BRIGHT-2 trial

Hangcheng Xu, Yan Wang, Qiang Sa, Yiran Zhou et autres

BACKGROUND: Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors combined with endocrine therapy have revolutionized the treatment landscape of hormone receptor (HR)-positive advanced breast cancer. However, reliable biomarkers for CDK4/6 inhibitors remain limited. This study investigated dynamic peripheral blood indicators as potential prognostic …

cn, us (code pays fourni par la source)

Efficacy and safety of vascular-targeting agents in advanced soft tissue sarcoma: a systematic review and network meta-analysis

Yan Wang, Hangcheng Xu, Qiang Sa, Yiran Zhou et autres

Background: Soft tissue sarcomas (STS) are rare, heterogeneous tumors with poor prognosis, often characterized by high recurrence rates and limited response to conventional chemotherapy in advanced stages. Vascular-targeting agents (VTA) have shown promising efficacy for STS in numerous clinical trials; however, the …

cn (code pays fourni par la source)

2740P Clinicopathological characteristics and prognositic analysis of malignant phyllodes tumor of the breast: A retrospective study

Ying Zhou, Chengye Guo, Yanling Wang, Hong Xu et autres

cn (code pays fourni par la source)

Clinicopathological Features and Prognostic Implications of HER2-Low in Early-Stage Male Breast Cancer: A Retrospective Analysis

Qiang Sa, Hangcheng Xu, Yan Wang, Yiran Zhou et autres

cn (code pays fourni par la source)

The optimal choice and combination strategy of vascular-targeting therapy for patients with advanced soft tissue sarcoma: A systematic review and network meta-analysis.

Yan Wang, Hangcheng Xu, Qiang Sa, Yiran Zhou et autres

e23532 Background: Soft tissue sarcomas (STS) are rare, heterogeneous tumors with poor prognosis, often characterized by high recurrence rates and limited response to conventional chemotherapy, especially in advanced stages. Vascular-targeting agents (VTAs) have shown promising efficacy in treating advanced STS, yet optimal …

cn (code pays fourni par la source)

Clinicopathological features and prognostic implications of HER2-low in early-stage male breast cancer: A retrospective analysis.

Qiang Sa, Hangcheng Xu, Yan Wang, Yiran Zhou et autres

e12518 Background: The clinicopathological and prognostic features of HER2-low female breast cancer (BC) have been widely studied. Current knowledge suggests that HER2-low could be identified as a special entity for treatment. However, limited research has focused on the HER2-low subtype in early-stage …

cn (code pays fourni par la source)

Optimizing therapeutic strategies for metastatic triple-negative breast cancer with homologous recombination deficiency: A Bayesian network meta-analysis.

Hangcheng Xu, Yan Wang, Qiang Sa, Yiran Zhou et autres

e13142 Background: Homologous recombination deficiency (HRD) is a key molecular feature in a subset of triple-negative breast cancer (TNBC). The optimal treatment strategy for metastatic TNBC with HRD remains unclear despite multiple therapeutic options. Methods: A systematic search was performed in PubMed, …

cn (code pays fourni par la source)